The molecular classification of EC, particularly mismatch repair deficiency, has proven essential in identifying tumors that are likely to respond to immune checkpoint inhibitors, owing to their increased tumor mutational burden and higher PD-L1 expression. The gene discussed is CD274; the disease is neoplasm.